$EVFM
Evofem Biosciences, Inc.

2015 Q1 Form 10-Q Financial Statement

#000156459016019174 Filed on May 12, 2016

View on sec.gov

Income Statement

Concept 2015 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.940M
YoY Change 76.36%
% of Gross Profit
Research & Development $4.701M
YoY Change 240.63%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $6.638M
YoY Change 167.13%
Operating Profit -$6.638M
YoY Change 167.13%
Interest Expense -$260.0K
YoY Change -129.55%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.900M
YoY Change 331.25%
Income Tax
% Of Pretax Income
Net Earnings -$6.902M
YoY Change 330.8%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$3.026M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.70M
YoY Change
Cash & Equivalents $70.72M
Short-Term Investments
Other Short-Term Assets $800.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $71.48M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $241.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K
YoY Change
Total Long-Term Assets $441.0K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $71.48M
Total Long-Term Assets $441.0K
Total Assets $71.92M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.898M
YoY Change
Accrued Expenses $1.591M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $487.7K
YoY Change
Total Short-Term Liabilities $3.976M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $9.300M
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $9.300M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.976M
Total Long-Term Liabilities $9.300M
Total Liabilities $13.28M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$76.58M
YoY Change
Common Stock $135.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $58.64M
YoY Change
Total Liabilities & Shareholders Equity $71.92M
YoY Change

Cashflow Statement

Concept 2015 Q1
OPERATING ACTIVITIES
Net Income -$6.902M
YoY Change 330.8%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$4.800M
YoY Change 72.66%
INVESTING ACTIVITIES
Capital Expenditures $226.1K
YoY Change 8537.43%
Acquisitions
YoY Change
Other Investing Activities -$200.0K
YoY Change
Cash From Investing Activities -$430.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -4.800M
Cash From Investing Activities -430.0K
Cash From Financing Activities 0.000
Net Change In Cash -5.230M
YoY Change -201.75%
FREE CASH FLOW
Cash From Operating Activities -$4.800M
Capital Expenditures $226.1K
Free Cash Flow -$5.026M
YoY Change 80.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
19737
CY2016Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
265124
CY2015Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
271846
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-6026556
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-6902380
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13757582
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13671311
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
17776
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3802
CY2015Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-6139
CY2016Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
39793
CY2015Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
46846
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
714687
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
299086
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-901697
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-164195
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3253731
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1578915
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7606334
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4803397
CY2015Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
200000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
226128
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-426128
CY2016Q1 neot Early Repayment Of Debt
EarlyRepaymentOfDebt
5514058
CY2016Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
485942
CY2016Q1 us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
52400
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-6052400
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5229525
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70717991
CY2015Q1 us-gaap Interest Paid
InterestPaid
225000
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p></div>
CY2016Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held.</p></div>
CY2016Q1 neot Noncancelable Operating Lease Agreement Date
NoncancelableOperatingLeaseAgreementDate
2015-01-20
CY2016Q1 neot Lease Expiration Period
LeaseExpirationPeriod
2020-03
CY2016Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1191835
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1485060
CY2016Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
279547
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
279547
CY2016Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
110951
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
93175
CY2016Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
71257
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1363027
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
157500
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
49180
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
350769
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1120578
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.09
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.97
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.25
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
714687
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
299086
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2056004
CY2016Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3684014
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
286893
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
395520
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
410850
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
431508
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
109293
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1634064

Files In Submission

Name View Source Status
0001564590-16-019174-index-headers.html Edgar Link pending
0001564590-16-019174-index.html Edgar Link pending
0001564590-16-019174.txt Edgar Link pending
0001564590-16-019174-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
neot-10q_20160331.htm Edgar Link pending
neot-20160331.xml Edgar Link completed
neot-20160331.xsd Edgar Link pending
neot-20160331_cal.xml Edgar Link unprocessable
neot-20160331_def.xml Edgar Link unprocessable
neot-20160331_lab.xml Edgar Link unprocessable
neot-20160331_pre.xml Edgar Link unprocessable
neot-ex103_38.htm Edgar Link pending
neot-ex311_7.htm Edgar Link pending
neot-ex321_8.htm Edgar Link pending
neot-ex47_37.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending